MINERALYS THERAPEUTICS, INC. Investing Cash Flow
MINERALYS THERAPEUTICS, INC. (MLYS) reported Investing Cash Flow of -$230.16 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Cash Flow › Investing Activities
us-gaap:NetCashProvidedByUsedInInvestingActivities · last filed 2026-08-11
- MINERALYS THERAPEUTICS, INC. net cash provided by (used in) investing activities for the quarter ending 2026-06-30 was -$185.22M.
- MINERALYS THERAPEUTICS, INC. net cash provided by (used in) investing activities for the quarter ending 2026-03-31 was -$44.94M.
- MINERALYS THERAPEUTICS, INC. net cash provided by (used in) investing activities for the quarter ending 2025-12-31 was -$103.49M, a 223.84% decline year-over-year.
- MINERALYS THERAPEUTICS, INC. net cash provided by (used in) investing activities for the quarter ending 2025-09-30 was -$150.51M, a 289.07% decline year-over-year.
- MINERALYS THERAPEUTICS, INC. net cash provided by (used in) investing activities for fiscal 2025 was -$389.75M, a 439.04% decline from fiscal 2024.
- MINERALYS THERAPEUTICS, INC. net cash provided by (used in) investing activities for fiscal 2024 was $114.96M.
- MINERALYS THERAPEUTICS, INC. net cash provided by (used in) investing activities for fiscal 2023 was -$160.47M.
- MINERALYS THERAPEUTICS, INC. net cash provided by (used in) investing activities for fiscal 2022 was -$21.76M.
| Period end | Net Cash Provided by (Used in) Investing Activities 3 month | Net Cash Provided by (Used in) Investing Activities 6 month | Net Cash Provided by (Used in) Investing Activities 9 month | Net Cash Provided by (Used in) Investing Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$185.22M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$230.16M 10-Q · filed 2026-08-11 | -$333.65M derived: sum of 3 quarters · filed 2026-08-11 | -$484.16M derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | -$44.94M 10-Q · filed 2026-05-06 | -$148.43M derived: sum of 2 quarters · filed 2026-05-06 | -$298.94M derived: sum of 3 quarters · filed 2026-05-06 | -$341.82M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-12-31 | -$103.49M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | -$254.00M derived: sum of 2 quarters · filed 2026-03-12 | -$296.88M derived: sum of 3 quarters · filed 2026-08-11 | -$389.75M 10-K · filed 2026-03-12 |
| 2025-09-30 | -$150.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | -$193.39M derived: sum of 2 quarters · filed 2026-08-11 | -$286.26M 10-Q · filed 2025-11-10 | -$202.69M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-06-30 | -$42.88M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | -$135.76M 10-Q · filed 2026-08-11 | -$52.19M derived: sum of 3 quarters · filed 2026-08-11 | $27.42M derived: sum of 4 quarters · filed 2026-08-11 |
| 2025-03-31 | -$92.88M 10-Q · filed 2026-05-06 | -$9.31M derived: sum of 2 quarters · filed 2026-05-06 | $70.30M derived: sum of 3 quarters · filed 2026-05-06 | $78.03M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $83.57M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-12 | $163.18M derived: sum of 2 quarters · filed 2026-03-12 | $170.91M derived: sum of 3 quarters · filed 2026-03-12 | $114.96M 10-K · filed 2026-03-12 |
| 2024-09-30 | $79.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $87.34M derived: sum of 2 quarters · filed 2025-11-10 | $31.39M 10-Q · filed 2025-11-10 | $23.30M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $7.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-12 | -$48.22M 10-Q · filed 2025-08-12 | -$56.30M derived: sum of 3 quarters · filed 2025-08-12 | -$52.30M derived: sum of 4 quarters · filed 2025-08-12 |
| 2024-03-31 | -$55.95M 10-Q · filed 2025-05-12 | -$64.04M derived: sum of 2 quarters · filed 2025-05-12 | -$60.03M derived: sum of 3 quarters · filed 2025-05-12 | -$76.17M derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$8.09M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-12 | -$4.08M derived: sum of 2 quarters · filed 2025-02-12 | -$20.22M derived: sum of 3 quarters · filed 2025-02-12 | -$160.47M 10-K · filed 2025-02-12 |
| 2023-09-30 | $4.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$12.13M derived: sum of 2 quarters · filed 2024-11-12 | -$152.38M 10-Q · filed 2024-11-12 | -$102.38M derived: sum of 4 quarters · filed 2024-11-12 |
| 2023-06-30 | -$16.14M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | -$156.39M 10-Q · filed 2024-08-13 | -$106.39M derived: sum of 3 quarters · filed 2024-08-13 | -$178.15M derived: sum of 4 quarters · filed 2024-08-13 |
| 2023-03-31 | -$140.25M 10-Q · filed 2024-05-09 | -$90.25M derived: sum of 2 quarters · filed 2024-05-09 | -$162.01M derived: sum of 3 quarters · filed 2024-05-09 | -$162.01M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $50.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-21 | -$21.76M derived: sum of 2 quarters · filed 2024-03-21 | -$21.76M derived: sum of 3 quarters · filed 2024-03-21 | -$21.76M 10-K · filed 2024-03-21 |
| 2022-09-30 | -$71.76M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | -$71.76M derived: sum of 2 quarters · filed 2023-11-07 | -$71.76M 10-Q · filed 2023-11-07 | |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | $0.00 10-Q · filed 2023-08-07 | ||
| 2022-03-31 | $0.00 10-Q · filed 2023-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |